For a long time, a lack of new treatment options has left respiratory physicians ‘plugging the holes’ in the leaky bucket that is severe asthma. But over the last few years a number of novel treatments, including monoclonal antibodies, have acquired Pharmaceutical Benefits Scheme (PBS) funding.1 Importantly, additional, innovative small molecule inhibitors are under clinical ...
Navigating the changing landscape of severe asthma management
Sponsored by Novartis Pharmaceuticals Australia Pty Ltd
22 Oct 2019